BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

Stopped This decision was conducted by the sponsor and not driven by safety concerns as no new safety signals have been observed in the CCR8 program.

Conditions

• Advanced Solid Tumor
• Metastatic Solid Tumor
• Solid Tumor

Interventions

• DRUG: BGB-A3055
• DRUG: Tislelizumab
• DRUG: Chemotherapy

Sponsor

BeiGene